| Keywords: |
cancer survival; overall survival; clinical trial; cancer combination chemotherapy; diarrhea; dose response; drug efficacy; monotherapy; patient selection; risk benefit analysis; treatment duration; antineoplastic agents; drug approval; drug targeting; cancer adjuvant therapy; disease free survival; chemotherapy, adjuvant; cancer staging; metastasis; breast cancer; epidermal growth factor receptor 2; antineoplastic activity; drug effect; breast neoplasms; risk factor; antibodies, monoclonal; drug mechanism; heart failure; cardiotoxicity; heat shock protein 90 inhibitor; clinical decision making; receptor, erbb-2; taxane derivative; trastuzumab; anthracycline; breast metastasis; heart left ventricle ejection fraction; drug contraindication; congestive heart failure; lapatinib; drug dose sequence; maytansine; pertuzumab; drug indication
|
